INTRODUCTION

Acellular matrix has revolutionized implant-based breast reconstruction since its introduction in 2004 for breast reconstruction. At present, 65% of implant-based breast reconstructions are performed with the use of acellular matrix. Typically, acellular matrix serves to reinforce the lower breast pocket and stabilize the implant or expander. In this capacity, it provides surgeons with an alternative soft tissue option to recruiting adjacent muscles and fascia. Over time, other benefits to its use have been realized, notably improving cosmetic outcome and reducing the risk of capsular contracture.

Several acellular matrix products are currently available for use in breast reconstruction, including human-derived [FlexHD (Ethicon, Somerville, N.J.); AlloDerm Regenerative Tissue Matrix (RTM, LifeCell, Branchburg, N.J.), AlloDerm RTM Ready To Use (RTU, LifeCell, Branchburg, N.J.); Neoform (Mentor, Santa Barbara, Calif.), DermaMatrix (Synthes, West Chester, Pa.), and DermACELL (NOVADAQ, Bonita Springs, Fla.); porcine-derived (Permacol {Covidien, Boulder, Colo.} and Strattice {LifeCell, Branchburg, N.J.)]; and bovine-derived (SurgiMend {Integra, Plainsboro, N.J.})] matrices. In addition}

**Background:** AlloDerm Ready To Use (RTU) is a sterile version of AlloDerm regenerative tissue matrix, developed in response to concerns regarding the potential risk of infectious complications with the latter aseptic matrix. Clinical data on AlloDerm RTU use is, however, limited, particularly with respect to histologic evidence of graft integration and clinical outcomes.

**Methods:** Consecutive patients who underwent tissue-expander/implant reconstruction with the use of AlloDerm RTU from March 2011 to September 2012 were included in this analysis. Biopsies of AlloDerm RTU/capsule interface were obtained at the time of expander/implant exchange and evaluated for evidence of cellularization, vascularization, and inflammatory reaction. Data on postoperative complications were retrieved from patient records.

**Results:** A total of 116 biopsy specimens from 68 patients were obtained. At biopsy, on visual inspection, nearly all grafts were fully integrated within the host tissue. Histologically, graft specimens demonstrated mild-to-moderate neovascularization and cellular repopulation with no inflammatory cells. All patients were followed for 5 years postoperatively. Short-term postoperative complications of skin necrosis, seroma, and infection occurred in 10.3%, 4.3%, and 2.6% of reconstructions, respectively. Capsular contracture (grade 3) was the only long-term complication (5.2%). Rates of short- and long-term complications are similar to those observed in our previous experience with AlloDerm reconstructive tissue matrix.

**Conclusions:** AlloDerm RTU used in breast reconstructive surgery fully integrates and incorporates into host tissue. There were no unexpected safety concerns with its use at short-term or at long-term, at least up to 5 years of follow-up.

Allen Gabriel, MD*

G. Patrick Maxwell, MD†

*From the *Department of Plastic Surgery, Loma Linda University Medical Center, Loma Linda, Calif.; and †Department of Plastic Surgery, Loma Linda University Medical Center, Loma Linda, Calif.

Received for publication October 16, 2017; accepted February 12, 2018.

Copyright © 2018 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. DOI: 10.1097/GOX.0000000000001744

Disclosure: This study was funded by LifeCell Corporation, Branchburg, N.J., through an Investigator Initiated Research Grant. Funds received were utilized for protocol development, data collection, histology processing and analyses, and article development and publication. Study authors and personnel received no compensation. The Article Processing Charge was paid for by the authors.
to the variability in the source, these products also vary with respect to processing. Consequently, variability in outcome is to be expected from their use. There is, how-
ever, limited data to guide their use with the exception of AlloDerm RTM, the first acellular matrix marketed for breast reconstruction. Even with AlloDerm RTM, variable outcomes have been reported, particularly with respect to rates of infection and seroma, with some studies reporting higher rates relative to total submuscular implant cover-
age.10–13 Because AlloDerm RTM is aseptic and not sterile, there have been concerns that this could be a potential contributing factor to higher incidences of infection. To address this concern, a sterile version of this matrix, Al-
loDerm RTU, was introduced in 2011.

As a relatively new product, clinical data on AlloDerm RTU in breast reconstruction is limited.14–20 This study was undertaken to report on the clinical performance of Al-
loDerm RTU in 2-stage, tissue expander/implant breast reconstruction, specifically with respect to histologic evidence of graft integration and clinical outcomes.

PATIENTS AND METHODS

This retrospective, single-center, single-surgeon, co-
hort study enrolled consecutive patients who underwent 2-stage, tissue-expander/implant breast reconstruction with the use of AlloDerm RTU from March 2011 to Sep-
tember 2012. Patients who underwent revision breast re-
construction, breast aesthetic surgery, or a combination of expander and autologous tissue flap reconstruction were excluded. The study protocol was approved by Peace-
Health Southwest Medical Center Institutional Review Board (Vancouver, Wash.).

Following mastectomy for oncologic or prophylactic rea-
sions, patients underwent immediate breast reconstruc-
tion with low- or moderate-height tissue expand-
ers. AlloDerm RTU (8 × 16 cm) was prepared according to manufacturer’s instructions and positioned and su-
tured at the lower breast pole, as previously described for other acellular dermal matrix products.5,21–24 Patients were discharged within 2–3 days and closely monitored for the development of postoperative complications at regular intervals. Typically, after 3 months of tissue ex-
pansion, patients’ expanders were exchanged for “per-
manent” implants. In patients who were scheduled to undergo postoperative radiotherapy or chemotherapy, expander exchange was delayed until completion of ad-
juvant treatment.

At the time of expander/implant exchange, punch biopsies of AlloDerm RTU/muscle-capsule interface were obtained from all patients. Specimens were immediately fixed in 10% neutral-buffered formalin and sent to an in-
dependent pathologist for processing and histopathologic examination. Processing involved dehydration through a graded series of reagent alcohol from 70% to 100%, clear-
ning in xylene substitute, and embedding in paraffin. The paraffin blocks were sliced into 4- to 5-µm thick sections, mounted on standard glass microscope slides, and stained with Harris Hematoxylin and Eosin-Y and Verhoeff’s van Geison. Prepared sections were evaluated for presence/absence and extent of cellularization (fibroblast density), vascularization (capillary density), and inflammatory reaction (inflammatory cell density). Cell and capillary density were scored semiquantitatively as none (absence of cells), mild, moderate, or significant. Clinical graft integration was evaluated qualitatively by gross observation. Presence of seroma and/or loose AlloDerm RTU was taken as evidence for nonintegration of graft.

After each stage of breast reconstruction, all incidences of postoperative complications, including infection, skin necrosis/dehiscence, hematoma, seroma, expander/implant loss, and clinically significant capsular contracture (Baker grade 3 or 4) were assessed and recorded by the re-
constructive surgeon (A.G.). Patient demographic infor-
mation (age and body mass index), clinical characteristics (smoking status, hypertension, diabetes, and obesity), and neoadjuvant and/or adjuvant therapy use (preoperative and postoperative chemotherapy and/or radiation ther-
apy) were obtained from patient records. The influence of these patient variables on outcomes was assessed.

RESULTS

Sixty-eight patients who underwent AlloDerm RTU-assisted, immediate, tissue expander/implant reconstruc-
tion were included in this analysis. Forty-eight patients had bilateral and 20 patients had unilateral mastectomies. Sixty percentage of the mastectomies were nipple-sparing (Table 1). Patients had a mean age of 53 years. The majority of patients were relatively healthy, with a mean body mass index of 26 kg/m². Twenty-two percentage of pa-
tients had comorbidities. Neoadjuvant/adjuvant therapy was prevalent, with 43% of patients having had chemother-
apy and 17% radiotherapy.

One hundred sixteen AlloDerm RTU biopsy speci-
mens were obtained, 1 from each breast, during ex-
pander/implant exchange. Specimens were obtained at a mean of 6.0 ± 4.0 months from expander placement

Table 1. Patient Demographics, Comorbidities, and Chemo- and/or Radiotherapy

| Description                                           | Value  |
|-------------------------------------------------------|--------|
| Patients, n                                           | 68     |
| Breasts, n                                            | 116    |
| Age (yr)                                              |        |
| Mean                                                  | 52.6   |
| Range                                                 | 25–70  |
| Body mass index (kg/m²)                               |        |
| Mean                                                  | 25.5±4.9|
| Range                                                 | 18.2–40.0|
| Comorbidities, no. patients (%)                        |        |
| Yes                                                    | 15 (22.1) |
| No                                                     | 53 (77.9) |
| Obesity†                                               |        |
| Yes                                                    | 13 (19.1) |
| No                                                     | 55 (80.9) |
| Diabetes mellitus                                      |        |
| Type 1                                                 | 1 (1.5) |
| Type 2                                                 | 1 (1.5) |
| Nipple-sparing mastectomy, no. breast (%)             |        |
| Yes                                                    | 70 (60.3) |
| No                                                     | 46 (39.7) |
| Radiation, no. breast (%)                             |        |
| Yes                                                    | 20 (17.2) |
| No                                                     | 58 (82.8) |
| Preoperative (percentage of irradiated breasts)       |        |
| Yes                                                    | 3 (25.0) |
| No                                                     | 12 (75.0) |
| Chemotherapy, no. patients (%)                         |        |
| Yes                                                    | 29 (42.6) |
| No                                                     | 39 (57.4) |
| Preoperative (percentage of patients with chemotherapy)|        |
| Yes                                                    | 16 (55.2) |
| No                                                     | 12 (44.8) |

†Defined as ≥30 kg/m².
At the time of biopsy, on visual inspection, all grafts were fully integrated within the host tissue, with the exception of 1. Integrated grafts appeared healthy, had no signs of foreign body reaction (encapsulation, resorption, or contracture), and demonstrated punctate bleeding (Fig. 1). Gross graft integration was confirmed histologically. Graft specimens demonstrated mild-to-moderate neovascularization and cellular (fibroblast) repopulation (Figs. 2, 3). Inflammatory cells were absent. At the graft/capsule interface, synovia-like metaplasia was observed within the capsule and absent within the graft (Fig. 4). Elastin staining revealed the demarcation of graft from capsular tissue, with the former showing an abundance and the latter showing an absence of elastin (Fig. 4).

In the 1 graft that was not fully integrated, pockets of loose unintegrated graft were noted. In the integrated portions of the graft, vascularization was noted, and interestingly, there was no evidence of inflammation or foreign body reaction. At expander/implant exchange, the unincorporated area was excised and the patient had an uneventful clinical course.

During expander/implant exchange, 16 implants in 8 patients were placed prepectorally. Plane conversion from subpectoral to prepectoral was undertaken in these patients because of complaints of pain and discomfort. Short-term postoperative complications of skin necrosis (12 cases) and seroma (5 cases) occurred in 10.3% and 4.3% of reconstructions, respectively. Three of the 5 cases of seroma (2.6%) had positive cultures, without visible signs of infection and were treated with intravenous antibiotics following seroma drainage. Four patients (7 breasts) died during follow-up due to their metastatic disease. Each of the remaining 64 patients was followed for 5 years postoperatively.

Long-term complications were limited to clinically significant capsular contracture (Baker grade 3) in 6 breasts (6 patients) for a capsular contracture rate of 5.2% (Fig. 5). Patients who had capsular contracture had no commodities, but 3 had radiotherapy (2 postoperatively and 1 preoperatively), 5 had chemotherapy (3 postoperatively and 2 preoperatively), and 2 had both radiotherapy and chemotherapy. On univariate analysis, only radiotherapy was significantly associated with the development of capsular contracture, while only chemotherapy, chemother and radiotherapy, and no treatment (no chemo- and or
radiotherapy) did not significantly increase the odds of developing capsular contracture (Table 2). Patients who had irradiation only had an approximately 22 times increased odds of developing contracture. Patients who had capsular contracture were treated with corrective surgery that included capsulotomy and implant exchange. One patient who had preoperative radiotherapy required the addition of a latissimus flap. All patients, including those who had corrective surgery for capsular contracture, had successful outcomes (Fig. 6).

DISCUSSION

AlloDerm RTU is derived from donated human skin and is processed in a similar manner to AlloDerm RTM. The core tissue processing is identical for both matrices up until the last few steps. AlloDerm RTM is stored in cryoprotective solution and freeze dried while AlloDerm RTU is stored in preservation solution (phosphate buffered solution) and terminally sterilized by electron beam radiation. Before use, AlloDerm RTM requires a rehydration step that may take up to 40 minutes depending on the thickness of the matrix, but usually 20 minutes for most
breast surgery purposes. AlloDerm RTU does not require rehydration as it is supplied rehydrated but a minimal soak time of 2 minutes before use is recommended to remove preservatives.

As the core tissue-processing step is identical to both matrices, implanted AlloDerm RTU is expected to vascularize, cellularize, and integrate into host tissue in a similar manner to AlloDerm RTM. Although an unpublished primate study demonstrated similar integration of the 2 matrices, there are no published data on AlloDerm RTU integration in the clinical setting.

In this series of 68 patients, we demonstrate that AlloDerm RTU placed at the lower pole during stage 1 reconstruction fully integrates within the host tissue by the time of expander/implant exchange. Integration was confirmed histologically by the presence of neovascularization and cellular repopulation within the graft, which is consistent with tissue viability. Moreover, the mild-to-moderate capillary and fibroblast density and the collagen orientation within the grafts are consistent with those seen in native human skin. It is of importance to highlight here that a common misconception among reconstructive surgeons is that a fully integrated graft should demonstrate robust or significant vessel and fibroblast density. In actuality, a healthy fully integrated graft should have mild-to-moderate vessel and fibroblast density. Significant vessel and fibroblast density is, in fact, a sign of chronic inflammatory response. Fully integrated AlloDerm RTU in our series did not show evidence of chronic inflammatory response, which is consistent with the presence of mild-to-moderate vessel and fibroblast density. In addition, the absence of synovia-like metaplasia within the integrated graft along the graft/cap-

| Risk Factor                  | Capsular Contracture Events (%) | OR (95% CI) | P     |
|------------------------------|---------------------------------|-------------|-------|
| Radiotherapy only            |                                 |             |       |
| Yes                          | 50.0                            | 21.8 (1.18–401.46) | 0.038* |
| No                           | 4.4                             |             |       |
| Chemotherapy only†           |                                 |             |       |
| Yes                          | 9.1                             | 2.7 (0.51–13.95)  | 0.245 |
| No                           | 3.6                             |             |       |
| Radiotherapy + chemotherapy† |                                 |             |       |
| Yes                          | 11.1                            | 2.9 (0.50–17.39)  | 0.235 |
| No                           | 4.1                             |             |       |
| No radiotherapy or chemotherapy† |                               |             |       |
| Yes                          | 0                               | NE          | NE    |
| No                           | 11.3                            |             |       |

*aStatistically significant at P < 0.05.
†Computed at the breast level.
NE, nonestimable.

Fig. 6. A 50-year-old who underwent left mastectomy followed by immediate AlloDerm RTU-assisted expander/implant reconstruction and right augmentation with round silicone implants (style 45, 650 cc on left and style 20 400 cc on right) and fat grafting x 1. (A–C) Preoperative, (D–F) 1-year postoperative, and (G–I) 3-year postoperative views.
surgery. 

Surgery within the host tissue following breast reconstructive surgery has been shown to decrease the risk of infectious complications reported with its non-sterile counterpart.10–13 A recent study by Zenn and Salzberg14 also attests to the low infection rate (0.8%) with this matrix. Other published series on AlloDerm RTU, however, have reported higher infection rates, ranging from 6.0% to 25.0%.15–17,19,20 Although it is difficult to comment on the disparity in infection rates between studies, we believe that strict adherence to aseptic techniques is critical to minimizing the risk, even when using a sterile graft.

Clinically significant capsular contraction was the only long-term complication in our series, in 6 breasts (6 patients). The contraction rate of 5.2% with AlloDerm RTU is similar to our previous experience with AlloDerm RTM (4.5%; Table 3) and within the range (0–10%) reported for AlloDerm RTM in the published literature.6,9,23,31 At the time of expander/implant exchange, there was no indication that these 6 breasts would develop contracture. There was no evidence of fibrosis or foreign body response histologically and by gross observation. Although univariate analysis found significant association between radiotherapy only and the development of capsular contracture, the impact of chemotherapy cannot be excluded, given the low incidence of contracture in this study. The absence of comorbidities (obesity, diabetes, and hypertension) in these patients precluded the evaluation of these variables as potential risk factors for the development of contracture.

This study is limited by the retrospective study design and the absence of an AlloDerm RTM internal control group, although a historic AlloDerm RTM cohort was used to compare postoperative complications. Notwithstanding these limitations, this study provides the first clinical evidence of AlloDerm RTU graft integration and incorporation within the host tissue following breast reconstructive surgery. 

### Table 3. Complications with AlloDerm RTU Versus AlloDerm RTM

| Complications                        | RTU (N = 116), n (%) | RTM (N = 157), n (%) | P    |
|--------------------------------------|----------------------|----------------------|------|
| Skin necrosis                        | 12 (10.3)            | 19 (12.2)            | 0.70 |
| Major                                | 6 (5.2)              | 10 (6.4)             | 0.80 |
| Intermediate                         | 6 (5.2)              | 7 (4.5)              | 0.78 |
| Minor                                | 0 (0)                | 2 (1.3)              | 0.51 |
| Seroma                               | 5 (4.3)              | 12 (7.6)             | 0.32 |
| Infection                            | 3 (2.6)              | 12 (7.6)             | 0.105|
| Exposure/loss of implant             | 0 (0)                | 8 (5.1)              | 0.02 |
| Capsular contracture                 | 6 (5.2)              | 7 (4.5)              | 0.78 |

Data for AlloDerm RTM were derived from the authors’ previous experience with this matrix. P values were computed using Fisher’s exact test.

### CONCLUSIONS

AlloDerm RTU used in breast reconstructive surgery fully integrates and incorporates into host tissue. There were no unexpected safety concerns with its use, both at short and long term, at least up to 5 years of follow-up.

### ACKNOWLEDGEMENTS

The authors thank Kalanethee Paul-Pletzer, PhD (PeaceHealth Southwest Medical Center, Vancouver, Wash.), for providing medical writing support and Vadim A. Pletzer for providing data analyses support for this article.

### REFERENCES

1. American Society of Plastic Surgeons. 2016 Plastic surgery statistics report.
2. Breuing KH, Warren SM. Immediate bilateral breast reconstruction with implants and inferolateral AlloDerm slings. *Ann Plast Surg* 2005;55:232–239.
3. Salzberg CA. Nonexpansive immediate breast reconstruction using human acellular tissue matrix graft (AlloDerm). *Ann Plast Surg* 2006;57:1–5.
4. Zienowicz RJ, Karacagloğlu E. Implant-based breast reconstruction with allograft. *Plast Reconstr Surg* 2007;120:373–381.
5. Spear SL, Parikh PM, Reisin E, et al. Acellular dermis-assisted breast reconstruction. *Aesthetic Plast Surg* 2008;32:418–425.
6. Vardanian AJ, Clayton JL, Roostaeian J, et al. Comparison of implant-based immediate breast reconstruction with and without acellular dermal matrix. *Plast Reconstr Surg* 2011;128:403e–410e.
7. Ho G, Nguyen TJ, Shahabi A, et al. A systematic review and meta-analysis of complications associated with acellular dermal matrix-assisted breast reconstruction. *Ann Plast Surg* 2012;68:346–356.
8. Forsberg CG, Kelly DA, Wood BC, et al. Aesthetic outcomes of acellular dermal matrix in tissue expander/implant-based breast reconstruction. *Ann Plast Surg* 2014;72:516–520.
9. Salzberg CA, Ashikari AV, Berry C, et al. Acellular dermal matrix-assisted direct-to-implant breast reconstruction and capsular contracture: a 13-year experience. *Plast Reconstr Surg* 2016;138:329–337.
10. Phillips BT, Bishawi M, Dagum AB, et al. A systematic review of infection rates and associated antibiotic duration in acellular dermal matrix breast reconstruction. *Eplasty* 2014;14:e42.
11. Seth AK, Persing S, Connor CM, et al. A comparative analysis of cryopreserved versus prehydrated human acellular dermal matrices in tissue expander breast reconstruction. *Ann Plast Surg* 2013;70:632–635.
12. McCarthy CM, Lee CN, Halvorson EG, et al. The use of acellular dermal matrices in two-stage expander/implant reconstruction: a multicenter, blinded, randomized controlled trial. *Plast Reconstr Surg* 2012;130:575–585.
13. Hill JL, Wong L, Kemper P, et al. Infectious complications associated with the use of acellular dermal matrix in implant-based bilateral breast reconstruction. *Ann Plast Surg* 2012;68:432–434.
14. Buseman J, Wong L, Kemper P, et al. Comparison of sterile versus nonsterile acellular dermal matrices for breast reconstruction. *Ann Plast Surg* 2013;70:497–499.
15. Weichman KE, Wilson SC, Saadeh PB, et al. Sterile “ready-to-use” AlloDerm decreases postoperative infectious complica-
tions in patients undergoing immediate implant-based breast reconstruction with acellular dermal matrix. *Plast Reconstr Surg*. 2013;132:725–736.

16. Yuen JC, Yue CJ, Erickson SW, et al. Comparison between freeze-dried and ready-to-use AlloDerm in alloplastic breast reconstruction. *Plast Reconstr Surg Glob Open*. 2014;2:e119.

17. Frey JD, Alperovich M, Weichman KE, et al. Breast reconstruction using contour fenestrated AlloDerm: does improvement in design translate to improved outcomes? *Plast Reconstr Surg Glob Open*. 2015;3:e505.

18. Zenn MR, Salzberg CA. A direct comparison of AlloDerm-ready to use (RTU) and DermACELL in immediate breast implant reconstruction. *Eplasty*. 2016;16:e23.

19. Klein GM, Nasser AE, Phillips BT, et al. Is sterile better than aseptic? Comparing the microbiology of acellular dermal matrices. *Plast Reconstr Surg Glob Open*. 2016;4:e761.

20. Pittman TA, Fan KL, Knapp A, et al. Comparison of different acellular dermal matrices in breast reconstruction: the 50/50 study. *Plast Reconstr Surg*. 2017;139:521–528.

21. Becker S, Saint-Cyr M, Wong C, et al. AlloDerm versus DermaMatrix in immediate expander-based breast reconstruction: a preliminary comparison of complication profiles and material compliance. *Plast Reconstr Surg*. 2009;123:1–6; discussion 107.

22. Rawlani V, Buck DW 2nd, Johnson SA, et al. Tissue expander breast reconstruction using prehydrated human acellular dermis. *Ann Plast Surg*. 2011;66:595–597.

23. Glasberg SB, Light D. AlloDerm and Strattice in breast reconstruction: a comparison and techniques for optimizing outcomes. *Plast Reconstr Surg*. 2012;129:1225–1233.

24. Venturi ML, Mesbah AN, Boehmler JH 4th, et al. Evaluating sterile human acellular dermal matrix in immediate expander-based breast reconstruction: a multicenter, prospective, cohort study. *Plast Reconstr Surg*. 2013;131:9e–18c.

25. AlloDerm® Regenerative Tissue Matrix. *Instructions for use*. Branchburg, NJ: LifeCell Corporation. 2011.

26. AlloDerm® Regenerative Tissue Matrix Ready To Use. *Instructions for use*. Branchburg, NJ: LifeCell Corporation. 2015.

27. LifeCell Corporation. *Data on file*.

28. Fernandez TL, Van Lonkhuyzen DR, Dawson RA, et al. Characterization of a human skin equivalent model to study the effects of ultraviolet B radiation on keratinocytes. *Tissue Eng Part C Methods*. 2014;20:588–598.

29. Bosset S, Bonnet-Duquennoy M, Barré P, et al. Photoageing shows histological features of chronic skin inflammation without clinical and molecular abnormalities. *Br J Dermatol*. 2003;149:826–835.

30. Jones GE, Harper JR. Technologic advances in breast surgery. In: *Bostwick’s Plastic and Reconstructive Breast Surgery*. Third Edition. Thieme Medical Publishers, Incorporated. Publication date: 07/01/2010.

31. Spear SL, Seruya M, Rao SS, et al. Two-stage prosthetic breast reconstruction using AlloDerm including outcomes of different timings of radiotherapy. *Plast Reconstr Surg*. 2012;130:1–9.